$MCK

Smith LeAnn B sold $1.3M of MCK

Smith LeAnn B (EVP & Chief HR Officer) sold 1,810 shares of MCKESSON CORP (MCK) at $735.50 ($1.33M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Smith LeAnn B
Published Jun 2, 2026, 7:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 7:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MCK
Neutral
medium confidence
Mentioned
$MCK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

The disclosed sale is executed under a pre-arranged Rule 10b5-1 plan, which generally lowers the probability that the trade is based on material nonpublic information.

02

Market read

Traders may monitor insider activity for sentiment, but this specific 10b5-1 sale is unlikely to drive a durable repricing.

03

What to watch

The filing doesn’t disclose reasons for the sale or any offsetting buys; net insider activity over a longer window would be more informative than a single transaction.

Relevance 6/10Novelty 6/10Timing: Filed today; sale executed on 2026-06-01

Background

The article is an SEC Form 4 insider transaction disclosure for McKesson (MCK).

Company-level read

Ticker impact

$MCKNeutralMedium confidence
Context

McKesson disclosed an EVP & Chief HR Officer open-market sale of 1,810 shares under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any move would be more sentiment-driven than fundamental.

Evidence & confidence

The filing is an ownership-change disclosure (Form 4) with a pre-arranged 10b5-1 plan, which reduces the likelihood of information leakage.

Market effects

Minimal; this is company-specific insider activity without stated operational/regulatory catalysts.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can reflect ongoing portfolio rebalancing rather than bearish information; price reaction may be overstated.

Key entities

  • McKesson Corp

    Subject of the Form 4 insider transaction disclosure.

  • LeAnn B. Smith

    EVP & Chief HR Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

$MCKHighAI 9/10

McKesson & CD&R Acquire Leading US Home-Infusion Platform

McKesson and private equity firm CD&R will acquire Option Care Health, a US home-infusion care provider, for $5.8bn. CD&R will take a majority stake, while McKesson invests $1.4bn for a minority stake. The deal values Option Care Health at $32.05 per share and is expected to close in H1 2027. McKesson aims to leverage the acquisition to expand its specialty care offerings.

$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

$MCKHighAI 9/10

McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout

McKesson plans a $1.4B investment for a 49% stake in Option Care Health, part of a $5.8B buyout by Clayton, Dubilier & Rice. Shareholders will receive $32.05 per share. The deal, pending approvals, is expected to close in early 2027. Option Care shares rose 32.7% on the news. McKesson's Q1 revenue grew 8% to $105.4B, with net income down 22% to $614M.